|
Palo Alto, CA, September 4, 2007 — Telik, Inc. (Nasdaq: TELK)
announced that company management will provide a corporate overview
at the 20th Annual Bear Stearns Healthcare Conference in
New York City on Tuesday, September 11, 2007 at 11:30 a.m. Eastern
time (8:30 a.m. Pacific time). Telik’s presentation will be webcast
live and will be available for replay through the Telik website,
www.telik.com, through September 18, 2007.
Telik, Inc. of Palo Alto, CA is a
biopharmaceutical company focused on discovering, developing and
commercializing novel small molecule drugs to treat serious
diseases. The company’s most advanced drug development candidates
are TELCYTA®, a tumor-activated small molecule product candidate in
clinical development for the treatment of advanced ovarian cancer
and non-small cell lung cancer; and TELINTRA™, which is in clinical
development for the treatment of myelodysplastic syndrome. Telik’s
product candidates were discovered using its proprietary drug
discovery technology, TRAP™, which enables the rapid and efficient
discovery of small molecule drug candidates.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2007 Press Releases2006
Press Releases
2005
Press ReleasesEvents |
